Venture • Life Science

The BroadOak Fund Invests In Sanguine BioSciences

On January 9, 2023, growth capital firm The BroadOak Fund invested in life science company Sanguine BioSciences

Investment Context
  • This is The BroadOak Fund’s 20th transaction in the Life Science sector.
  • This is The BroadOak Fund’s 23rd transaction in the United States.
  • This is The BroadOak Fund’s 2nd transaction in Massachusetts.

Explore All 557 Venture Life Science Deals - Search the Database Free


Investment Summary

Date January 9, 2023
Target Sanguine BioSciences
Sector Life Science
Investor(s) The BroadOak Fund
Deal Type Venture

Target Company

Sanguine BioSciences

Woburn, Massachusetts, United States
Sanguine BioSciences engages in-home specimen collection and a leader in direct-to-patient recruitment and digital health innovation. Sanguine BioSciences bridging the gap between patients and researchers to accelerate discovery and development. Sanguine BioSciences is based in Woburn, Massachusetts.
Explore More Deals

Browse All 215,262 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investor Overview 1

DESCRIPTION

The BroadOak Fund is the investment affiliate of life science focused investment bank BroadOak Capital Partners. The BroadOak Fund provides growth capital to life sciences tools and service providers that have achieved a level of commercial success. The BroadOak Fund is based in Bethesda, Maryland.


Deal Context for Investor #
Overall 25 of 26
Sector: Life Science 20 of 21
Type: Venture 7 of 7
State: Massachusetts 2 of 2
Country: United States 23 of 24
Year: 2023 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-09 CDI Laboratories

Mayaguez, Puerto Rico

CDI Laboratories is the nextGen proteomics company, a result of intensive efforts and advances made by synthetic biologists at the Johns Hopkins University School of Medicine. The company was created by scientists for scientists to address critical needs required accelerate research, advance discoveries, and translate these discoveries into novel products and services that improve human health. CDI Laboratories is based in Mayaguez, Puerto Rico.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-01-23 Emvenio Research

Durham, North Carolina, United States

Emvenio Research is a decentralized research organization (DRO) providing scalable and hybrid decentralized trial solutions with a focus on improving access and health equity in clinical research. Emvenio Research is based in Durham, North Carolina.

Sell -